Tudor Investment Corp ET AL Buys Shares of 23,966 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Tudor Investment Corp ET AL acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 23,966 shares of the company's stock, valued at approximately $991,000.

A number of other large investors have also bought and sold shares of MIRM. Jones Financial Companies Lllp lifted its stake in Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the last quarter. R Squared Ltd bought a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $69,000. AlphaQuest LLC lifted its holdings in Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after purchasing an additional 1,658 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Mirum Pharmaceuticals by 8.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock valued at $172,000 after purchasing an additional 312 shares during the last quarter. Finally, Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $189,000.

Mirum Pharmaceuticals Stock Performance

MIRM traded up $0.91 during trading on Monday, hitting $45.18. 47,605 shares of the company traded hands, compared to its average volume of 523,991. Mirum Pharmaceuticals, Inc. has a one year low of $23.83 and a one year high of $54.23. The stock's fifty day moving average is $42.82 and its 200 day moving average is $44.30. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm has a market cap of $2.23 billion, a P/E ratio of -22.35 and a beta of 0.95.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter last year, the business posted ($0.54) EPS. Mirum Pharmaceuticals's quarterly revenue was up 61.2% compared to the same quarter last year. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 7,879 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $348,330.59. Following the completion of the transaction, the chief operating officer now owns 18,672 shares of the company's stock, valued at $825,489.12. The trade was a 29.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Peetz sold 27,279 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now owns 138,641 shares of the company's stock, valued at $6,129,318.61. This trade represents a 16.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 92,764 shares of company stock valued at $4,109,161. 14.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on MIRM shares. JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a "market outperform" rating in a report on Friday. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. Finally, HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $59.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.